Linfomas
GLUN
![Foto de Linfomas](/img/uploaded/b9af73325528959212d2c665099d4e1f.jpg)
![Foto de Medical University of Vienna](/img/noimage_org.png)
Medical University of Vienna
Viena, AustriaPublicacións en colaboración con investigadores/as de Medical University of Vienna (6)
2022
-
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33
-
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494
-
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
Cancers, Vol. 14, Núm. 3
2021
-
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310
-
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Journal of Hematology and Oncology
2020
-
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
The Lancet Haematology, Vol. 7, Núm. 7, pp. e511-e522